Click on headlines below to download research

COVID-19 stockpiling positive impact
Laboratorios Farmacéuticos ROVI | 18/05/2020

Laboratorios Farmacéuticos ROVI (ROVI) reported Q120 operating revenue of €101.0m (+23% y-o-y), driven by strong growth both in the speciality…

More data support vafidemstat for aggression
Oryzon Genomics | 14/04/2020

On 3 April 2020, Oryzon reported interim data for the first time from its two Phase IIa trials REIMAGINE-AD and ETHERAL. Both explore the company’s…

Executive interview
Executive interview - Laboratorios Farmacéuticos ROVI | 06/04/2020

ROVI is a profitable speciality healthcare company that markets ~40 proprietary and in-licensed products across nine core franchises, mainly in its domestic…

Investing for future growth
Laboratorios Farmacéuticos ROVI | 28/02/2020

Laboratorios Farmacéuticos ROVI has reported a strong set of FY19 results, with all pillars of the business contributing to revenue growth of 26%…

More to come after a year of data readouts
Oryzon Genomics | 20/01/2020

As we expected, 2019 was a year of data readouts for epigenetics specialist Oryzon. The company presented new data from the ongoing Phase IIa clinical…

CMO business driving growth
ADL Bionatur Solutions | 11/12/2019

ADL Bionatur Solutions’ (ADL-BS) 9M19 results show €2.16m adjusted EBITDA and 127% year-on-year operating revenue growth to €33.2m, driven…

Maturing ALICE trial dataset continues to impress
Oryzon Genomics | 10/12/2019

On 9 December 2019, Oryzon presented more data from the Phase II ALICE trial at the 61st ASH annual meeting in Orlando, Florida. The single-arm, open-label…

Multiple growth drivers lie ahead
Laboratorios Farmacéuticos ROVI | 04/12/2019

Following Laboratorios Farmacéuticos ROVI’s (ROVI’s) recent investor day, we have reviewed our near-term forecasts. Specifically, we…